NCT00082888已完成2 期
Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 93
- 试验地点
- 2
- 主要终点
- Proportion of Participants With Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment
研究概览
简要总结
This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tipifarnib may be an effective treatment for non-Hodgkin's lymphoma.
详细描述
PRIMARY OBJECTIVES:
I. To assess tumor response to R115777 (tipifarnib) in patients with relapsed aggressive non-Hodgkin's lymphoma. (Permanently closed to accrual 6/28/06) II. To assess tumor response to R115777 in patients with relapsed indolent non-Hodgkin's lymphoma. (Permanently closed to accrual 9/26/07) III. To assess tumor response to R115777 in patients with uncommon non-Hodgkin's lymphomas.
IV. To evaluate toxicity associated with this regimen in patients with relapsed non-Hodgkin's lymphoma.
SECONDARY OBJECTIVES:
I. To evaluate known and unknown molecular markers that may predict for response to R115777 in lymphoma tissue.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy-proven relapsed or refractory lymphomas; previous biopsies =< 6 months prior to treatment on this protocol will be acceptable as long as there has not been intervening therapy; if the patient has received therapy for non-Hodgkin's disease (NHL) between the time of the last biopsy and this protocol, then a re-biopsy is necessary
- •STUDY 1: Aggressive lymphomas (permanently closed to accrual 6/28/06):
- •Transformed lymphomas
- •Diffuse large B cell lymphoma
- •Mantle cell lymphoma
- •Follicular lymphoma grade III STUDY 2: Indolent lymphomas (permanently closed to accrual 9/26/07)
- •Small lymphocytic lymphoma/chronic lymphocytic leukemia
- •Follicular lymphoma, grades 1, 2
- •Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type
- •Nodal marginal zone B-cell lymphoma
- •Splenic marginal zone B-cell lymphoma
- •STUDY 3: Uncommon lymphomas:
- •Peripheral T cell lymphoma, unspecified
- •Anaplastic large cell lymphoma (T and null cell type)
- •Lymphoplasmacytic lymphoma
- •Mycosis fungoides/ Sezary syndrome
- •Relapsed Hodgkin's disease (patients must be previously treated and either have had a transplant or not be eligible for a transplant)
- •Previously treated (no limitations on the number of prior therapies); patients with aggressive lymphoma (Study 1 - permanently closed to accrual 6/28/06) should have received or be ineligible for potentially curable therapy including stem cell transplant
- •MEASURABLE DISEASE: Must have at least one lesion that has a single diameter of >= 2 cm or tumor cells in the blood >= 5 x10^9/L
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- •Absolute neutrophil count >=1000/mm^3
- •Platelet count >= 75,000
- •Hemoglobin >= 9 g/dL
- •Total bilirubin =< 2 x upper limit of normal (ULN) (if > 2 x ULN direct bilirubin is required and should be =< 1.5 x ULN)
- •Aspartate aminotransferase (AST) =< 3 x ULN (=< 5 x ULN if liver involvement is present)
- •Serum creatinine =< 2 x ULN
- •Expected survival >= 3 months
- •Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide valid informed consent
- •Capable of swallowing intact study medication tablets
- •Capable of following directions regarding taking study medication, or has a daily caregiver who will be responsible for administering study medication
排除标准
- •Any of the following as this regimen may be harmful to a developing fetus or nursing child:
- •Pregnant women
- •Breastfeeding women
- •Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.)
- •NOTE: The effects of R115777 on the developing human fetus at the recommended therapeutic dose are unknown
- •Life-threatening illness (unrelated to tumor)
- •Ongoing radiation therapy or radiation therapy =< 3 weeks prior to study registration unless the acute side effects associated with such therapy are resolved
- •Therapy with myelosuppressive chemotherapy, cytotoxic chemotherapy, or biologic therapy =< 3 weeks (6 weeks for nitrosourea or mitomycin C) or corticosteroids =< 2 weeks, prior to starting R11577; patients may be on corticosteroids or tapering off them up until the day they start R11577 as long as it is clear that they are not having a tumor response to the steroids or that the steroids would confuse the interpretation of response to R11577; patients may be receiving stable (not increased within the last month) chronic doses of corticosteroids with a maximum dose of 20 mg of prednisone per day if they are being given for disorders other than lymphoma such as rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, or intractable symptoms of lymphoma
- •Peripheral neuropathy >= grade 3
- •Serious non-malignant disease such as active infection or other condition which in the opinion of the investigator would compromise other protocol objectives
- •Presence of central nervous system (CNS) lymphoma
- •Other active malignancies
- •Once a patient begins FTI (tipifarnib) treatment, the addition of other cancer treatment will confound the assessment of efficacy and therefore is not allowed; this restriction precludes the addition of cytotoxic, immunologic agents, radiotherapy, or an increase in corticosteroid dose while the patient is in the treatment phase of this protocol
- •Known to be human immunodeficiency virus (HIV) positive; HIV testing is not required but should be done if clinically indicated; HIV patients are excluded because of concerns regarding excess risk of complications of immunosuppressive therapy regimens
- •Known allergy to imidazole drugs such as clotrimazole, ketoconazole, miconazole, econazole, fenticonazole, sulconazole, tioconazole, or terconazole
研究组 & 干预措施
Treatment (tipifarnib)
Experimental
Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
Treatment (tipifarnib)
Experimental
Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Tipifarnib (Drug)
结局指标
主要结局
Proportion of Participants With Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment
时间窗: During the first 6 cycles of treatment
Confirmed response is at least a 50% decrease in the sum of the products of the greatest diameters (SPD) of the six largest dominant nodes or nodal masses and no increase in the size of other nodes, liver, or spleen and splenic and hepatic nodules must regress by at least 50% in the SPD and no new sites of disease.
次要结局
- Overall Survival(Up to 2 years)
- Time to Progression(up to 2 years)
- Number of Patients Who Experienced Grade 3 or 4 Toxicities(Up to 56 days)
- Duration of Response(up to 2 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersAccelerated Phase of DiseaseAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase of DiseaseMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableRecurrent DiseaseChronic Myelomonocytic LeukemiaNCT02210858National Cancer Institute (NCI)31
已完成
2 期
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast CancerEstrogen Receptor-positive Breast CancerRecurrent Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerNCT00082810National Cancer Institute (NCI)33
已完成
2 期
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem GliomaChildhood High-grade Cerebral AstrocytomaChildhood OligodendrogliomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood MedulloblastomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaNCT00070525National Cancer Institute (NCI)90
已完成
2 期
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaNCT00602771National Cancer Institute (NCI)84
招募中
2 期
Tipifarnib and Naxitamab for Relapsed/Refractory NeuroblastomaNeuroblastomaNCT06540963Giselle Sholler98